The economic analyses indicate that neither amivantamab–lazertinib combination therapy nor lazertinib monotherapy represents a cost-effective first-line option for EGFR exon 20 insertion-positive NSCLC compared to osimertinib monotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.